期刊文献+

血清可溶性细胞间黏附分子1、透明质酸水平与Graves眼病疾病活动性之间的关系 被引量:1

Association of hyaluronic acid and soluble intercellular adhesion molecule-1 with the activity of Graves' ophthalmopathy
原文传递
导出
摘要 探讨可溶性细胞问黏附分子1(sICAM-1)和透明质酸(HA)能否反映Graves眼病(GO)的疾病活动性。用ELISA方法检测48例GO患者(眼病组)的sICAM-1、HA水平,同时检测30例单纯Graves甲状腺功能亢进患者作为对照组。与对照组相比,眼病组的血清sICAM-1、HA水平明显增高(P〈0.05);且眼病组活动期的血清sICAM-1、HA水平明显高于稳定期(P〈0.05)。Pearson相关性分析显示眼病组的血清sICAM-1、HA水平均与眼病活动分数(CAS)呈显著正相关(r=0.53,P〈0.01;r=0.46,P〈0.01),且sICAM-1与HA亦呈正相关(r=0.31,P〈0.05)。GO患者外周血sICAM-1、HA水平可作为评价GO活动性的指标。 To investigate weather serum soluble intercellular adhesion molecule-1 (sICAM-1) and hyaluronic acid(HA) levels can be used in assessing the disease activity of Graves' ophthalmopathy ( GO). Serum levels of sICAM-1 and HA were determined in 48 cases with GO and 30 cases with Graves' disease without GO (CON). Compared with the CON group, the levels of sICAM-1 and HA in GO cases were raised significantly(P〈 0. 05 ). sICAM-1 and HA levels in the subgroup of patients with active GO were markedly elevated when compared to those with stable GO( P〈0. 05 ). Pearson regression analysis showed that elevated levels of sICAM-1 and HA were positively correlated with the Clinical Activity Score (CAS) of GO ( r = 0. 53, P〈0. 01 ; r = 0.46, P〈0. 01 ) ; A significant correlation between sICAM-1 and HA( r=0. 31, P〈0. 05) was noted. The raised serum levels of sICAM-1 and HA may serve as two activity markers of GO.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2011年第10期830-832,共3页 Chinese Journal of Endocrinology and Metabolism
基金 国家自然科学基金资助项目(81070626)
关键词 格雷夫斯眼病 可溶性细胞间黏附分子1 透明质酸 相关性 Graves' ophthalmopathy Soluble intercellular adhesion molecule-1 Hyaluronic acid Association
  • 相关文献

参考文献23

  • 1Fernández Hermida RV,Pinar S,Muruzábal N.Clinical manifestations of thyroid ophthalmopathy.An Sist Sanit Navar,2008,31:45-56.
  • 2郭剑津(译),刘超(审校).Graves眼病的治疗:系统综述及meta分析[J].中华内分泌代谢杂志,2010,26(1):69-72. 被引量:2
  • 3孙治平,仲维学,缪珩,淤葛华,游娜,张学光.外周血CD4^+CD28^-T细胞表达的细胞因子与Graves眼病的相关性[J].中华内分泌代谢杂志,2010,26(1):39-40. 被引量:1
  • 4崔炯,王中心,杨芳.血清白介素6及其可溶性受体水平与Graves眼病活动性[J].中华内分泌代谢杂志,2004,20(3):244-245. 被引量:4
  • 5王坚,王扬天,邵加庆,赵明,王晓,杜宏.霉酚酸酯治疗甲状腺相关性眼病临床对照研究[J].医学研究生学报,2003,16(12):911-913. 被引量:7
  • 6Heufelder AE.Interactions of fibroblasts,adipocytes and immunocompeent cells in the pathogenesis of endocrine ophthalmopathy.Acta Med Austriaca,2001,28:89-92.
  • 7Raychaudhuri N,Douglas RS,Smith TJ.PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity:implications to thyroid-associated ophthalmopathy.PLoS One,2010,23:e15296-e15306.
  • 8Yan SX,Wang Y,Peng GJ,et al.Effects of technetium-99methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with Graves' ophthalmopathy.Nucl Med Commun,2011,32:142-146.
  • 9van Steensel L,Dik WA.The orbital fibroblast:a key player and target for therapy in Graves' ophthalmopathy.Orbit,2010,29:202-206.
  • 10Wong YK,Tang KT,Wu JC,et al.Stimulation of hyaluronan synthesis by interleukin-1β involves activation of protein kinase C βⅡ in fibroblasts from patients with Graves' ophthalmopathy.J Cell Biochem,2001,82:58-67.

二级参考文献21

  • 1GreenspanFS.基础与临床内分泌学,第五版.西安:世界图书出版社西安分公司,2001,246.
  • 2Pmnmel MM, Wiersinga MW. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol , 1997,47:9-14.
  • 3Kumar S, Bahn R. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves' ophthalmopathy. J Clin Endoerinol Metab,2003 ,88 :4246-4250.
  • 4Markovic-Plese S, Cortese I, Wandinger KP, et al. CD4^+ CD28^- costimulation-independent T cells in multiple sclerosis. J Clin Invest, 2001,108 : 1185-1194.
  • 5Komocsi A, Lamprech P, Csernok E, et al. Peripheral blood and granuloma CD4^+ CD28^-T cells are a major source of interferon-3, and tumor necrosis factor-α in Wegener's Granulomatosis. Am J Pathol, 2002,160 : 1717-1724.
  • 6SchirmerM, Vallejo AN, Weyand CM, et al. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4^+ CD28^-T cells from rheumatoid arthritis patients. J Immunol, 1998,161:1018-1025.
  • 7Mourits MP, Koorneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves′ ophthalmopathy: a novel approach. Br J Ophthalmol, 1989,73:639-644.
  • 8Salvi M, Girasole G, Pedrazzoni M, et al. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves′ disease. J Clin Endocrinol Metab, 1996,81:2976-2979.
  • 9Salvi M, Pedrazzoni M, Girasole G. Serum concentrations of proinflammatory cytokines in Graves′ disease: effect of treatment, thyroid function, ophthalmopathy and cigrette smoking. Eur J Endocrinol, 2000,143:197-202.
  • 10Werner SC. Modification of the classification of the eye change of Graves′ disease: Recommendation of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab, 1977,44:203-204.

共引文献10

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部